The primary aim of this study was to determine the levels of immune checkpoint expression on the peripheral B cell subsets in patients with CLL and to further correlate these immune checkpoints with B2M levels, a confirmed independent prognostic marker in patients with CLL [17]. The gene discussed is B2M; the disease is B-cell chronic lymphocytic leukemia.